Beta Bionics, Inc. (BBNX) Form 10-Q — Oct 27, 2026
Beta Bionics reported Q3 2026 net sales of $35.5 million, up 30% year over year, with nine-month revenue of $95.1 million up 40%. Gross margin expanded to 57% in the quarter (59% nine months) on production scale and lower warranty costs. Losses widened despite growth: Q3 net loss was $24.4 million, up 71% YoY, driven by 57% growth in sales and marketing and 46% growth in R&D. The company ended the quarter with $81.6 million in cash plus roughly $292 million in investments after a $161.3 million follow-on offering, with no debt.
Key figures
- Revenue
- 35505000
- Total Debt
- 0
- Revenue Yoy
- +30% (Q3); +40% nine months ($95.1M vs $68.1M)
- Total Assets
- 443759000
- Cash Position
- 81551000
- Shares Outstanding
- 54367067
- Mint launch
- Q1 2027, capacity of at least 1.5M disposable units in 2027
- Gross margin q3
- 57%
- T2d pivotal trial
- enrollment completed October 2026, potential mid-2027 clearance goal
- Nine month net loss
- 69651000
- Long term investments
- 133436000
- Short term investments
- 158653000
- Gross margin nine months
- 59% vs 54% prior year
- Pbp channel share of sales
- 38% vs 21% prior year
- Single use products share q3
- 68% of net sales vs 47% prior year
- Follow on offering net proceeds
- $161.3M (Sept 2026, ~8.96M shares, $11.2M offering costs)
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.